H-1B sponsorship profile: Sumitomo Pharma Oncology, Inc. Across U.S. Department of Labor LCA disclosures, Sumitomo Pharma Oncology, Inc filed 5 Labor Condition Applications covering 5 H-1B worker positions between fiscal year 2023 and fiscal year 2023. The employer’s DOL certification rate sits at 100% (5 certified of 5 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Sumitomo Pharma Oncology, Inc’s H-1B petitions range from $109,408 at the low end to $166,036 at the high end, with a petition-weighted average of $140,861. That range reflects the mix of occupations the company sponsors, led by Associate Director, Pharmacovigilance Systems (2 petitions at $166,036 avg), followed by Senior Manager, Accounting and Scientist I, Translational Biology . H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Sumitomo Pharma Oncology, Inc is headquartered in Marlborough, MA under NAICS code 54171, and places H-1B workers across 2 states, most heavily in MA, UT. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Sumitomo Pharma Oncology, Inc ranks. By H-1B petition volume, Sumitomo Pharma Oncology, Inc is #26,547 of 119,880 employers nationally and #1,208 of 5,193 employers headquartered in MA. Both ranks are computed live from the same underlying petition counts, not a separate estimate.